Represents the amount received for legal settlement.

No definition available.

Name:	abbv_LegalSettlementIncome
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyIndividualPlaintiffLawsuitsNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of purported class actions filed, pertaining to a loss contingency during the period.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyPurportedClassActionsNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Numbers of cases are consolidated for pre-trial purposes.

+ References

No definition available.

+ Details

Name:	abbv_NumberOfCasesConsolidatedForPreTrialPurposes
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of claims subject to settlement agreements

+ References

No definition available.

+ Details

Name:	abbv_PercentageofClaimsSubjecttoSettlementAgreements
Namespace Prefix:	abbv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents number of the number of individual putative class action lawsuit.

+ References

No definition available.

+ Details

Name:	abbv_PutativeClassActionLawsuitIndividualNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of loss contingency liability.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of damages awarded to the plaintiff in the legal matter.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of plaintiffs that have filed claims pertaining to a loss contingency.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_NiaspanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_TestosteroneReplacementTherapyProductsLiabilityLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_DepakoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_NovartisVaccinesandDiagnosticsIncandGrifolsWorldwideOperationsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_PatentLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_DisgorgementRemedyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Legal Proceedings and Contingencies (Details)	1 Months Ended						9 Months Ended		12 Months Ended
Legal Proceedings and Contingencies (Details)	Sep. 30, 2019 direct_purchaser	Jun. 30, 2018 USD ($)	Mar. 31, 2017	Jun. 30, 2016 investment_fund	Nov. 30, 2014 individual	Sep. 30, 2014 company	Sep. 30, 2019 direct_purchaser	Sep. 30, 2019 end_payor_purchaser	Dec. 31, 2019 USD ($) company claim lawsuit class_action	Dec. 31, 2018 USD ($)
Legal Proceedings and Contingencies
Recorded accrual balance for litigation									$ 290,000,000	$ 350,000,000
Number of individual putative class action lawsuit \| individual					5
Percentage of claims subject to settlement agreements									80.00%
AndroGel Antitrust Litigation
Legal Proceedings and Contingencies
Recorded accrual balance for litigation									$ 0
Number of generic companies with whom certain litigation related agreements were entered into \| company						2
Number of healthcare benefit providers who filed lawsuits \| direct_purchaser	2
Niaspan
Legal Proceedings and Contingencies
Number of healthcare benefit providers who filed lawsuits							1	1
Elliott Associates, L.P.
Legal Proceedings and Contingencies
Number of parties to lawsuit (in investment funds) \| investment_fund				5
Testosterone Replacement Therapy Products Liability Litigation
Legal Proceedings and Contingencies
Numbers of cases are consolidated for pre-trial purposes \| claim									3,500
Number of cases pending \| claim									175
Depakote
Legal Proceedings and Contingencies
Number of cases pending \| claim									120
Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd
Legal Proceedings and Contingencies
HCV-related patents			11
Patent Litigation \| AndroGel Antitrust Litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company									3
Patent Litigation \| Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit									4
Number of purported class actions \| class_action									2
Disgorgement Remedy \| AndroGel Antitrust Litigation
Legal Proceedings and Contingencies
Damages awarded against company		$ 448,000,000
Other operating income
Legal Proceedings and Contingencies
Legal settlement income									$ 550,000,000